



PART - I							
Statement of standalone Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2021							
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		(Rs. in lakhs)
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	Year ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	31.03.2021
						(Audited)	
1	Income from Operations						
	(a) Revenue from Operations	1,650.50	1,415.79	1,545.36	4,103.58	4,343.76	5,964.90
	(b) Other operating Income	17.81	13.44	16.05	33.82	50.22	52.44
	Total Income from operations (net)	1,668.31	1,429.23	1,561.41	4,137.40	4,393.98	6,017.34
2	Expenses						
	(a) Cost of material consumed	1,130.89	870.88	987.32	2,652.13	2,548.63	3,418.99
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	78.33	-80.40	-76.86	-125.25	100.05	152.99
	(d) Employee benefit expense	141.95	182.09	192.07	490.22	515.90	720.79
	(f) Finance Cost	14.29	23.94	14.09	53.50	52.89	74.35
	(g) Depreciation and amortisation expense	19.01	20.06	22.07	59.26	66.02	88.07
	(h) Other expenses	183.65	262.17	267.07	626.64	781.74	1,018.79
	Total expenses	1,568.12	1,278.75	1,405.76	3,756.50	4,065.23	5,473.99
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	100.19	150.47	155.65	380.90	328.75	543.35
4	Exceptional items	-	-	-	-	-	37.13
5	Profit(+)/Loss(-) before tax (3+4)	100.19	150.47	155.65	380.90	328.75	506.22
6	Taxes of earlier years	-	-	-	-	-	-
7	Current Tax	-21.22	-39.86	-33.04	-95.88	-82.74	-127.00
8	Deferred tax(benefit/expense)	-	-	-	-	-	24.60
9	Total Tax expense	-21.22	-39.86	-33.04	-95.88	-82.74	-102.40
10	Net movement in regulatory deferral account balances related to Profit or loss and the related deferred tax movement	-	-	-	-	-	-
11	Profit(+)/Loss(-) for the period from continuing operation (5-9)	78.97	110.62	122.61	285.02	246.01	403.82
12	Profit(+)/Loss(-) from discontinued operations before tax	-	-	-	-	-	-
13	Tax expense of discontinued operations	-	-	-	-	-	-
14	Net Profit(loss) for the period from discontinued operations	-	-	-	-	-	-
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	-	-	-	-	-	-
16	Total profit(loss) for period	78.97	110.62	122.61	285.02	246.01	403.82
17	Other comprehensive Income net of taxes	-	-	-	-	-	-
18	Net profit(loss) for period	78.97	110.62	122.61	285.02	246.01	403.82
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03
	Other Equity						2,724.19
20	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						
	(a) Basic	0.062	0.087	0.097	0.225	0.194	0.319
	(b) Diluted	0.062	0.087	0.097	0.225	0.194	0.319

Standalone Notes:

- The standalone unaudited financial results of Gennex Laboratories Limited('the Company') have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 'Interim Financial Reporting' Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 ('the Act'), read with the Companies (Indian Accounting Standard) Rule, 2015, as amended from time to time and other accounting principles generally accepted in India.
- The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on February 14, 2022. The Statutory auditors have carried out limited review of the above results for the quarter and nine months ended December 31, 2021. An unmodified report has been issued by them thereon.
- The Company operating segment is "Bulk Drugs" Manufacturing as its deals mainly with Guaifenesin, Methocarbamol, it also does business outside India. The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.
- The Company continues to monitor the possible effects that may result from the pandemic relating to COVID-19. The Company continues to take several business continuity measures with a view to ensure minimal disruption with respect to operations including production and distribution activities. The Company has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity in other markets. Based on Internal and external sources of information current economic environment and future economic indicators, the Company has assessed the financial impact of the COVID-19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. Wherever considered necessary an assessment of the impact has been carried out and the necessary adjustments if material have been recorded. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Company will continue to monitor any material changes to future economic conditions.
- Previous period's figures have been rearranged / regrouped wherever necessary
- The quarterly unaudited standalone financial results for the Quarter and Nine Months ended December 31, 2021 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com.

For Gennex Laboratories Limited

Date: 14.02.2022
Place: Hyderabad

Arihant Baid
Managing Director
DIN: 01171845



PART - I							
Statement of Consolidated Unaudited Financial Results for the Quarter and Nine months ended 31 December, 2021							
Sl. No.	Particulars	Quarter Ended			Nine Months Ended		(Rs. in lakhs)
		31.12.2021 (Unaudited)	30.09.2021 (Unaudited)	31.12.2020 (Unaudited)	31.12.2021 (Unaudited)	31.12.2020 (Unaudited)	Year ended 31.03.2021 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	1,650.50	1,415.79	1,545.36	4,103.58	4,343.76	5,964.90
	(b) Other operating Income	17.81	13.44	16.05	33.82	50.22	52.44
	Total Income from operations (net)	1,668.31	1,429.23	1,561.41	4,137.40	4,393.98	6,017.34
2	Expenses						
	(a) Cost of material consumed	1,130.89	870.88	987.32	2,652.13	2,548.63	3,418.99
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	78.33	-80.40	-76.86	-125.25	100.05	152.99
	(d) Employee benefit expense	141.95	182.09	192.07	490.22	515.90	720.79
	(f) Finance Cost	14.29	23.94	14.09	53.50	52.89	74.35
	(g) Depreciation and amortisation expense	19.01	20.06	22.07	59.26	66.02	88.07
	(h) Other expenses	183.65	262.17	267.07	626.64	781.74	1,018.79
	Total expenses	1,568.12	1,278.75	1,405.76	3,756.50	4,065.23	5,473.99
3	Profit(+)/Loss(-) from operations before exceptional items and tax (1-2)	100.19	150.47	155.65	380.90	328.75	543.35
4	Exceptional items	-	-	-	-	-	37.13
5	Profit(+)/Loss(-) before tax (3+4)	100.19	150.47	155.65	380.90	328.75	506.22
6	Taxes of earlier years	-	-	-	-	-	-
7	Current Tax	-21.22	-39.86	-33.04	-95.88	-82.74	-127.00
8	Deferred tax(benefit/expense)	-	-	-	-	-	24.60
9	Total Tax expense	-21.22	-39.86	-33.04	-95.88	-82.74	-102.40
10	Net movement in regulatory deferral account balances related to Profit or loss and the related deferred tax movement	-	-	-	-	-	-
11	Profit(+)/Loss(-) for the period from continuing operation (5-9)	78.97	110.62	122.61	285.02	246.01	403.82
12	Profit(+)/Loss(-) from discontinued operations before tax	-	-	-	-	-	-
13	Tax expense of discontinued operations	-	-	-	-	-	-
14	Net Profit(loss) for the period from discontinued operations	-	-	-	-	-	-
15	Share of Profit(loss) of associates and Joint Ventures accounted for using equity method	-	-	-	-	-	-
16	Total profit(loss) for period	78.97	110.62	122.61	285.02	246.01	403.82
17	Other comprehensive Income net of taxes	-	-	-	-	-	-
18	Net profit(loss) for period	78.97	110.62	122.61	285.02	246.01	403.82
19	Paid-up Equity Share Capital (Face value Rs. 1 each Equity Share)	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03	1,265.03
	Other Equity						2,705.94
20	Earning Per Equity Share (EPS) (Face value of Rs 1 per Share) (of Rs. 1 each) (not annualised) :						
	(a) Basic	0.062	0.087	0.097	0.225	0.194	0.319
	(b) Diluted	0.062	0.087	0.097	0.225	0.194	0.319

Consolidated Notes:

1. The Consolidated unaudited financial results of Gennex Laboratories Limited('the Company') have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 'Interim Financial Reporting' Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 ('the Act'), read with the Companies (Indian Accounting Standard) Rule, 2015, as amended from time to time and other accounting principles generally accepted in India.

2. The above Consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on February 14, 2022. The Statutory auditors have carried out limited review of the above results for the quarter and nine months ended December 31, 2021. An unmodified report has been issued by them thereon.

3. The Company operating segment is "Bulk Drugs" Manufacturing as its deals mainly with Guaifenesin, Methocarbamol, it also does business outside India. The Company operates in single segment and therefore the Segment Reporting as per AS-17 is not applicable for the Company.

4. The Company continues to monitor the possible effects that may result from the pandemic relating to COVID-19. The Company continues to take several business continuity measures with a view to ensure minimal disruption with respect to operations including production and distribution activities. The Company has not experienced any significant difficulties with respect to market demand, financing capital expansion projects, collections or liquidity in other markets. Based on Internal and external sources of information current economic environment and future economic indicators, the Company has assessed the financial impact of the COVID-19 situation on its operations particularly on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. Wherever considered necessary an assessment of the impact has been carried out and the necessary adjustments if material have been recorded. However, the impact of the pandemic could be different from those estimated today considering the uncertainties involved. The Company will continue to monitor any material changes to future economic conditions.

5. Previous period's figures have been rearranged / regrouped wherever necessary

6. The quarterly unaudited Consolidated Financial results for the Quarter and Nine Months ended December 31, 2021 are available on the Company's Website i.e., www.gennexlab.com and also available on BSE website i.e., www.bseindia.com.

For Gennex Laboratories Limited

Date: 14.02.2022
Place: Hyderabad

Arihant Baid
Managing Director
DIN: 01171845